Pharmacokinetic-pharmacodynamic evaluation of gepotidacin against gram-positive organisms using data from murine infection models

Antimicrobial Agents and Chemotherapy

Volumn 61, Issue 2, 2017, Pages

  Bulik, Catharine C ^a   Okusanya, Ólanrewaju O ^a,d   Lakota, Elizabeth A ^a   Forrest, Alan ^a   Bhavnani, Sujata M ^a   Hoover, Jennifer L ^b   Andes, David R ^c   Ambrose, Paul G ^a  

^a INSTITUTE FOR CLINICAL PHARMACODYNAMICS   (United States)

^b GLAXOSMITHKLINE   (United States)

^c UNIVERSITY OF WISCONSIN MADISON   (United States)

^d CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

Author keywords

Gepotidacin; Staphylococcus aureus; Streptococcus pneumoniae

Indexed keywords

GEPOTIDACIN; ACENAPHTHENE DERIVATIVE; ANTIINFECTIVE AGENT; FUSED HETEROCYCLIC RINGS;

ANIMAL EXPERIMENT; ANIMAL MODEL; AREA UNDER THE CURVE; ARTICLE; COLONY FORMING UNIT; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG EFFICACY; EPITHELIAL LINING FLUID; FEMALE; IN VIVO STUDY; LUNG INFECTION; MINIMUM INHIBITORY CONCENTRATION; MOUSE; NONHUMAN; POSTANTIBIOTIC EFFECT; PRIORITY JOURNAL; SINGLE DRUG DOSE; STAPHYLOCOCCAL PNEUMONIA; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS INFECTION; ANIMAL; DISEASE MODEL; DOSE RESPONSE; DRUG EFFECTS; INBRED MOUSE STRAIN; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; PNEUMOCOCCAL INFECTIONS; PNEUMONIA, STAPHYLOCOCCAL; STAPHYLOCOCCAL INFECTIONS; STREPTOCOCCUS PNEUMONIAE; THIGH;

ACENAPHTHENES; ANIMALS; ANTI-BACTERIAL AGENTS; AREA UNDER CURVE; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HETEROCYCLIC COMPOUNDS, 3-RING; MICE, INBRED STRAINS; MICROBIAL SENSITIVITY TESTS; PNEUMOCOCCAL INFECTIONS; PNEUMONIA, STAPHYLOCOCCAL; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS PNEUMONIAE; THIGH;

EID: 85010987703     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00115-16     Document Type: Article

References (28)

1. Musher DM, Thorner AR. 2014. Community-acquired pneumonia. N Engl J Med 371:1619-1628. https://doi.org/10.1056/NEJMra1312885.
2. Chambers HF. 2014. Pharmacology and the treatment of complicated skin and skin-structure infections. N Engl J Med 370:2238-2239. https://doi.org/10.1056/NEJMe1405078.
3. Mandell LA, Wunderink RG, Anzueto A, Bartlett JG, Campbell GD, Dean NC, Dowell SF, File TM, Jr, Musher DM, Niederman MS, Torres A, Whitney CG. 2007. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis 44:S27-S72. https://doi.org/10.1086/511159.
4. Kim ES, Hooper DC. 2014. Clinical importance and epidemiology of quinolone resistance. Infect Chemother 46:226-238. https://doi.org/10.3947/ic.2014.46.4.226.
5. Farrell DJ, Liverman LC, Biedenbach DJ, Flamm RK, Jones RN. 2011. Surveillance of JNJ-Q2 activity tested against Staphylococcus aureus and beta-hemolytic streptococci as a component of the 2010 SENTRY Antimicrobial Surveillance Program. Diagn Microbiol Infect Dis 71:415-420. https://doi.org/10.1016/j.diagmicrobio.2011.08.011.
6. Farrell DJ, Mendes RE, Ross JE, Sader HS, Jones RN. 2011. LEADER Program results for 2009: an activity and spectrum analysis of linezolid using 6,414 clinical isolates from 56 medical centers in the United States. Antimicrob Agents Chemother 55:3684-3690. https://doi.org/10.1128/AAC.01729-10.
7. Jones RN, Sader HS, Mendes RE, Flamm RK. 2013. Update on antimicrobial susceptibility trends among Streptococcus pneumoniae in the United States: report of ceftaroline activity from the SENTRY Antimicrobial Surveillance Program (1998-2011). Diagn Microbiol Infect Dis 75:107-109. https://doi.org/10.1016/j.diagmicrobio.2012.08.024.
8. Bax BD, Chan PF, Eggleston DS, Fosberry A, Gentry DR, Gorrec F, Giordano I, Hann MM, Hennessy A, Hibbs M, Huang J, Jones E, Jones J, Brown KK, Lewis CJ, May EW, Saunders MR, Singh O, Spitzfaden CE, Shen C, Shillings A, Theobald AJ, Wohlkonig A, Pearson ND, Gwynn MN. 2010. Type IIA topoisomerase inhibition by a new class of antibacterial agents. Nature 466:935-940. https://doi.org/10.1038/nature09197.
9. Bouchillon S, Hackel M, Miller LA, Scangarella-Oman NE. 2013. In vitro activity of GSK2140944, a novel topoisomerase inhibitor, against isolates associated with lower respiratory tract and skin infections, poster F-1216. Abstr 53rd Intersci Conf Antimicrob Agents Chemother, Denver, CO.
10. Tiffany CA, Hossain M, McDonald M, Lerman S, Dumont EF. 2014. Safety and pharmacokinetics of single escalating IV doses of GSK2140944, a novel bacterial topoisomerase inhibitor, poster 2611. Abstr 54th Intersci Conf Antimicrob Agents Chemother, Washington, DC.
11. Tiffany CA, Hossain M, McDonald M, Lerman S, Dumont EF. 2014. Safety and pharmacokinetics of repeat escalating IV doses of GSK2140944, a novel bacterial topoisomerase inhibitor, poster F-278. Abstr 54th Intersci Conf Antimicrob Agents Chemother, Washington, DC.
12. Hossain M, Tiffany CA, McDonald M, Dumont EF. 2014. Safety and pharmacokinetics of repeat escalating oral doses of GSK2140944, a novel bacterial topoisomerase inhibitor, poster 2320. Abstr 54th Intersci Conf Antimicrob Agents Chemother, Washington, DC.
13. Hossain M, Dumont EF. 2014. Population pharmacokinetic modeling of plasma and epithelial lining fluid data for a novel antimicrobial compound, poster 2313. Abstr 54th Intersci Conf Antimicrob Agents Chemother, Washington, DC.
14. Hoover JL, Mininger CL, Novick SJ, Rittenhouse SF. 2013. Efficacy of GSK2140944 against Streptococcus pneumoniae in a non-neutropenic mouse lung infection model, poster A-014. Abstr 53rd Intersci Conf Antimicrob Agents Chemother, Denver, CO.
15. Craig WA. 2007. Pharmacodynamics of antimicrobials: general concepts and applications, p 1-20. In Nightingale CH, Ambrose PG, Drusano GL, Murakawa T (ed), Antimicrobial pharmacodynamics in theory and clinical practice. Informa Healthcare, New York, NY.
16. Ambrose PG, Bhavnani SM, Rubino CM, Louie A, Gumbo T, Forrest A, Drusano GL. 2007. Pharmacokinetics-pharmacodynamics of antimicrobial therapy: it's not just for mice anymore. Clin Infect Dis 44:79-86. https://doi.org/10.1086/510079.
17. Andes D, Craig WA. 2002. Pharmacodynamics of the new fluoroquinolone gatifloxacin in murine thigh and lung infection models. Antimicrob Agents Chemother 46:1665-1670. https://doi.org/10.1128/AAC.46.6.1665-1670.2002.
18. Andes D, Craig WA. 2003. Pharmacodynamics of the new Des-F(6)-quinolone garenoxacin in a murine thigh infection model. Antimicrob Agents Chemother 47:3935-3941. https://doi.org/10.1128/AAC.47.12.3935-3941.2003.
19. Ambrose PG, Bhavnani SM, Owens RC. 2007. Quinolones, p 177-188. In Nightingale CH, Ambrose PG, Drusano GL, Murakawa T (ed), Antimicrobial pharmacodynamics in theory and clinical practice. Informa Healthcare, New York, NY.
20. GlaxoSmithKline. 2000. Dose-ranging study of GSK2140944 in the treatment of subjects with suspected or confirmed Gram-positive acute bacterial skin and skin structure infections. ClinicalTrials.gov identifier NCT02045797. https://clinicaltrials.gov/ct2/show/NCT02045797.
21. Bulik CC, Bhavnani SM, Hammel J, Forrest A, Dudley MN, Ellis-Grosse EJ, Drusano GL, Ambrose PG. 2013. Relationship between regulatory approval and pharmacokinetic-pharmacodynamic target attainment: focus on community- and hospital-acquired pneumonia, abstr A-295. Abstr 53rd Intersci Conf Antimicrob Agents Chemother, Denver, CO.
22. Craig WA. 1998. Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. Clin Infect Dis 26:1-10. https://doi.org/10.1086/516284.
23. Craig WA. 1993. Post-antibiotic effects in experimental infection models: relationship to in-vitro phenomena and to treatment of infections in man. J Antimicrob Chemother 31:149-158. https://doi.org/10.1093/jac/31.suppl-D.149.
24. Clinical and Laboratory Standards Institute. 2010. CLSI document M100-S20. CLSI, Wayne, PA.
25. Gerber AU, Vastola AP, Brandel J, Craig WA. 1982. Selection of aminoglycoside-resistant variants of Pseudomonas aeruginosa in an in vivo model. J Infect Dis 146:691-697. https://doi.org/10.1093/infdis/146.5.691.
26. Rennard SI, Basset G, Lecossier D, O'Donnel KM, Pinkston P, Martin PG, Crystal RG. 1986. Estimation of volume of epithelial lining fluid recovered by lavage using urea as marker of dilution. J Appl Physiol 60:532-538.
27. Bauer RJ. 2011. S-ADAPT/MCPEM user's guide: software for pharmacokinetic, pharmacodynamic, and population data analysis, version 1.57. Biomedical Simulations Resource, Los Angeles, CA.
28. Andes D, Craig WA. 2006. Pharmacodynamics of a new streptogramin, XRP 2868, in murine thigh and lung infection models. Antimicrob Agents Chemother 50:243-249. https://doi.org/10.1128/AAC.50.1.243-249.2006.